Sign In
Buy HRTX
$0.496
-0.0012 (-0.241%)
At Close: Jul 31, 2026
Heron Therapeutics: Changing Strategy After Disappointing Earnings
01:46am, Thursday, 03'rd Mar 2022 Seeking Alpha
Heron Therapeutics to Present at 42nd Annual Cowen Healthcare Conference | MarketScreener
09:06pm, Wednesday, 02'nd Mar 2022 MarketScreener
SAN DIEGO, March 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to… | March 2, 2022
Heron Therapeutics to Present at 42nd Annual Cowen Healthcare Conference
09:05pm, Wednesday, 02'nd Mar 2022 PR Newswire
SAN DIEGO, March 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that…
Heron Therapeutics: Changing Strategy After Disappointing Earnings
08:46pm, Wednesday, 02'nd Mar 2022
Heron Therapeutics had a productive 2021 with several corporate and commercial achievements that will set the company up for future growth.
Why Heron Therapeutics Stock Is Getting Hammered Today
08:38pm, Tuesday, 01'st Mar 2022 The Motley Fool
The biotech's Q4 results didn't live up to expectations.
Why Heron Therapeutics Stock Is Getting Hammered Today
08:38pm, Tuesday, 01'st Mar 2022 The Motley Fool
The biotech''s Q4 results didn''t live up to expectations.
Heron stock falls 21% as Q4 sales remain largely flat Y/Y
03:38pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Heron Therapeutics <> stock fell following in Q4 results.Q4 net product sales rose +0.24% Y/Y to $20.66M, which failed to beat analysts'' estimates. Net product sales for ZYNRELEF…
Why Heron Therapeutics Stock Is Getting Hammered Today
03:38pm, Tuesday, 01'st Mar 2022
The biotech's Q4 results didn't live up to expectations.
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
12:51pm, Tuesday, 01'st Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Editas Gains On Resolution Of CRISPR Gene Editing Patent Case
Editas Medicine, Inc. (NASDAQ: EDIT) sai
Heron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q4 2021 Results - Earnings Call Transcript
01:40am, Tuesday, 01'st Mar 2022 Seeking Alpha
Heron Therapeutics (HRTX) Reports Q4 Loss, Lags Revenue Estimates
10:45pm, Monday, 28'th Feb 2022 Zacks Investment Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 8.47% and 20.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics GAAP EPS of -$0.54 beats by $0.04, revenue of $20.66M misses by $5.11M
09:20pm, Monday, 28'th Feb 2022 Seeking Alpha
Heron Therapeutics press release (HRTX): Q4 GAAP EPS of -$0.54 beats by $0.04.Revenue of $20.66M (+0.2% Y/Y) misses by $5.11M.
Heron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q4 2021 Results - Earnings Call Transcript
08:40pm, Monday, 28'th Feb 2022
Heron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q4 2021 Results - Earnings Call Transcript
Heron Therapeutics (HRTX) Reports Q4 Loss, Lags Revenue Estimates
07:08pm, Monday, 28'th Feb 2022
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 8.47% and 20.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Scheduled For February 28, 2022
09:17am, Monday, 28'th Feb 2022 Benzinga
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ: LXRX ) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (NASDAQ: PRAX ) is likely to report earnings for its fourth quarter. • Blackstone Secured (NYSE: BXSL ) is likely to report quarterly earnings at $0.59 per share on revenue of $171.69 million. • Mersana Therapeutics (NASDAQ: MRSN ) is estimated to report earnings for its fourth quarter. • Partner Communications Co (NASDAQ: PTNR ) is expected to report earnings for its fourth quarter. • Daqo New Energy (NYSE: DQ ) is expected to report quarterly earnings at $4.58 per share on revenue of $698.65 million. • Easterly Government Props (NYSE: DEA ) is likely to report quarterly earnings at $0.10 per share on revenue of $72.20 million. • Aurinia Pharmaceuticals (NASDAQ: AUPH ) is expected to report earnings for its fourth quarter. • Kosmos Energy (NYSE: KOS ) is estimated to report quarterly earnings at $0.15 per share on revenue of $380.
